MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics director Barbara Ryan reported stock-based board compensation rather than open-market trades. On June 1, 2026, she received 1,434 shares of common stock valued at $12.38 per share as a grant in lieu of cash retainers, bringing her direct holdings to 23,469 shares.
The filing also reports a prior grant on March 2, 2026 of 1,629 shares at $10.90 per share, likewise received instead of cash board and committee fees. Footnotes explain these awards are restricted stock units that convert into one share each and vest one month after grant, and that the Q1 2026 RSUs were filed late due to an administrative error.
Corvese Brian reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Brian Corvese received stock-based board compensation rather than cash. He was granted 1,444 restricted stock units (RSUs) at $12.38 and 1,640 RSUs at $10.90 as compensation for board and committee retainers. The RSUs vest one month from each grant, and his direct common stock holdings total 53,137 shares after these awards. RSUs for Q1 2026 board and committee compensation were reported late due to an administrative error.
Behner Peter reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director Peter Behner reported stock-based board compensation. He received 1,313 restricted stock units on June 1, 2026 and 1,491 units on March 2, 2026, each convertible into common shares and granted in lieu of cash retainers. The RSUs vest one month after each grant, bringing his direct holdings to 22,919 common shares.
The company noted that the RSUs for Q1 2026 board and committee compensation were not filed on time due to an administrative error.
WIINBERG ULF reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Ulf Wiinberg reported stock-based board compensation rather than open-market trading. On June 1, 2026, he received 1,131 shares of Common Stock at $12.38 per share as a grant in lieu of cash retainers, bringing his direct holdings to 22,650 shares.
The filing also shows a prior grant of 1,285 shares on March 2, 2026 at $10.90 per share, with 21,519 shares held directly after that award. In addition, 27,830 shares are held indirectly in an irrevocable trust for the benefit of his family. Footnotes state these restricted stock units vest one month after grant and that the Q1 2026 grant was filed late due to an administrative error.
MiNK Therapeutics, Inc. reported a net loss of $2.7 million for the three months ended March 31, 2026, similar to the prior-year period. Research and development expense was $1.2 million while general and administrative expense rose to $1.7 million, mainly from higher share-based compensation and professional fees.
Cash and cash equivalents were $9.5 million as of March 31, 2026, and the company has an accumulated deficit of $159.4 million. It raised about $3.0 million via at-the-market stock sales in the quarter and an additional $150,000 afterward, and repaid a $5.0 million related-party convertible note in January 2026. Management states that while existing cash plus anticipated funding are expected to cover more than one year of liquidity needs, completion of funding is not fully within its control, so substantial doubt exists about its ability to continue as a going concern.
MiNK Therapeutics, Inc. reported first quarter 2026 financial results and highlighted progress advancing its allo-iNKT cell therapy platform. The company initiated a randomized Phase 2 trial of lead candidate agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026.
MiNK ended the quarter with approximately $9.5 million in cash and cash equivalents, down from about $13.4 million as of December 31, 2025. It repaid roughly $5.2 million related to an Agenus convertible note and raised about $3.0 million via its at-the-market sales agreement. Net loss was approximately $2.7 million, or $0.57 per share, versus about $2.8 million, or $0.70 per share, a year earlier.
MiNK Therapeutics is holding its 2026 Annual Meeting virtually on June 17, 2026 at 9:30 a.m. Eastern via live audio webcast. Stockholders of record on April 23, 2026, when 4,981,899 shares were outstanding, are entitled to vote.
Investors will vote on electing three Class II directors — Garo Armen, Barbara Ryan and John Holcomb — to three-year terms expiring at the 2029 meeting, and on ratifying KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. The board recommends voting FOR both proposals.
The filing details MiNK’s governance structure, committee memberships and director independence, and describes executive pay. In 2025, CEO Jennifer Buell received $448,000 in salary, a $350,000 stock-settled bonus and option grants with grant-date fair value of $1,284,195, for total compensation of $2,087,881, along with change‑in‑control and severance protections.
MiNK Therapeutics director John Bradley Holcomb received a grant of stock options covering 4,174 shares of common stock. The options have an exercise price of $14.92 per share and were awarded under the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan. They vest in three equal annual installments on September 23, 2026, 2027 and 2028, as long as Dr. Holcomb continues his service relationship with the company. Following this grant, he holds 4,174 options directly.
MiNK Therapeutics, Inc. Principal Financial Officer Melissa Orilall filed an initial Form 3 showing an existing indirect holding of common stock. The filing reports beneficial ownership of 222 shares held indirectly through her spouse, with no new buy or sell transaction disclosed.